AI Portfolio Summary
In 2025 Q4, Tri Locum Partners LP maintained a portfolio of 25 distinct positions. The most significant new addition to the portfolio was DANAHER CORPORATION, which now represents 10.31% of the total fund value. They heavily accumulated shares in JOHNSON & JOHNSON, increasing their position by 99.2%. Conversely, Tri Locum Partners LP completely exited their position in MERCK & CO INC.
Total Positions
25
Quarter
2025 Q4
Top Holding
JNJ (16.2%)
Top 10 Concentration
80.1%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 25
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
JNJ
JOHNSON & JOHNS...
|
Healthcare | 16.21% | 12.91% |
#1
Prev: #1
|
9.0 | 300,312 | 99.2% |
P
S
|
603,143 | $124,820,444 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DHR
DANAHER CORPORA...
|
Healthcare | 10.31% | — |
#2
Prev: #—
|
9.0 | 346,875 | no change |
NEW
|
346,875 | $79,406,625 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LLY
ELI LILLY & CO
|
Healthcare | 8.83% | — |
#3
Prev: #—
|
8.0 | 63,284 | no change |
NEW
|
63,284 | $68,010,049 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UTHR
UNITED THERAPEU...
|
Healthcare | 7.65% | 11.77% |
#4
2
Prev: #2
|
4.1 | -1,266 | -1.0% |
P
S
|
120,921 | $58,918,757 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 7.34% | 7.99% |
#5
Prev: #5
|
6.4 | 90,186 | 51.6% |
P
S
|
265,015 | $56,511,799 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MDGL
MADRIGAL PHARMA...
|
Healthcare | 6.50% | 7.14% |
#6
2
Prev: #8
|
5.1 | 18,317 | 27.1% |
P
S
|
86,023 | $50,094,634 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BSX
BOSTON SCIENTIF...
|
Healthcare | 6.44% | — |
#7
Prev: #—
|
6.1 | 520,508 | no change |
NEW
|
520,508 | $49,630,438 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TEVA
TEVA PHARMACEUT...
|
Healthcare | 5.82% | — |
#8
Prev: #—
|
5.8 | 1,435,865 | no change |
NEW
|
1,435,865 | $44,813,347 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IONS
IONIS PHARMACEU...
|
Healthcare | 5.72% | — |
#9
Prev: #—
|
5.8 | 557,174 | no change |
NEW
|
557,174 | $44,078,035 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 5.30% | 7.95% |
#10
4
Prev: #6
|
2.1 | -384,518 | -32.3% |
P
S
|
805,689 | $40,800,091 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AXSM
AXSOME THERAPEU...
|
Healthcare | 4.78% | 8.16% |
#11
7
Prev: #4
|
1.9 | -90,510 | -31.0% |
P
S
|
201,627 | $36,825,155 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARGX
ARGENX SE
|
Healthcare | 4.11% | 7.36% |
#12
5
Prev: #7
|
2.1 | -5,758 | -13.3% |
P
S
|
37,653 | $31,664,290 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NUVL
NUVALENT INC
|
Healthcare | 4.01% | — |
#13
Prev: #—
|
5.1 | 307,371 | no change |
NEW
|
307,371 | $30,918,449 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DXCM
DEXCOM INC
|
Healthcare | 3.63% | — |
#14
Prev: #—
|
5.0 | 421,600 | no change |
NEW
|
421,600 | $27,981,592 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 3.33% | 1.65% |
#15
Prev: #15
|
4.3 | 439,536 | 240.4% |
P
S
|
622,403 | $25,649,228 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRK
MERCK & CO INC
|
Healthcare | 0.00% | 8.62% |
Sold All 😨
(Was: #3) |
0.0 | -446,874 | -100.0% |
CLOSED
|
— | $— | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLNO
SOLENO THERAPEU...
|
Healthcare | 0.00% | 7.00% |
Sold All 😨
(Was: #9) |
0.0 | -450,585 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABBV
ABBVIE INC
|
Healthcare | 0.00% | 4.77% |
Sold All 😨
(Was: #10) |
0.0 | -89,621 | -100.0% |
CLOSED
|
— | $— | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KRRO
KORRO BIO INC
|
Healthcare | 0.00% | 3.72% |
Sold All 😨
(Was: #11) |
0.0 | -337,764 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 0.00% | 3.38% |
Sold All 😨
(Was: #12) |
0.0 | -366,102 | -100.0% |
CLOSED
|
— | $— | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AVDL
AVADEL PHARMACE...
|
Healthcare | 0.00% | 2.54% |
Sold All 😨
(Was: #13) |
0.0 | -724,859 | -100.0% |
CLOSED
|
— | $— | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
STVN
STEVANATO GROUP...
|
Healthcare | 0.00% | 1.97% |
Sold All 😨
(Was: #14) |
0.0 | -332,912 | -100.0% |
CLOSED
|
— | $— | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 0.00% | 1.63% |
Sold All 😨
(Was: #16) |
0.0 | -119,260 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 0.00% | 0.93% |
Sold All 😨
(Was: #17) |
0.0 | -75,986 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BHVN
BIOHAVEN LTD
|
Healthcare | 0.00% | 0.51% |
Sold All 😨
(Was: #18) |
0.0 | -149,179 | -100.0% |
CLOSED
|
— | $— | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 25 holdings